House Resolution 8083 is a commemorative resolution that recognizes July 2025 as "Fibroid Awareness Month" in Florida. The resolution describes uterine fibroids as benign tumors of the uterus and notes their prevalence, symptoms, and health impacts, including heavy menstrual bleeding, pain, infertility, fetal mortality, and the frequent need for hysterectomy. It also references the Florida House’s prior designation of July as Fibroid Awareness Month in 2015 and frames the observance as a way to continue public education and awareness.
The resolution does not create new regulatory requirements, funding, or enforcement provisions. Its legal effect is limited to an official state recognition and public-awareness observance, with no changes to the Florida Statutes or administrative rules. The practical impact is symbolic and educational, intended to encourage earlier diagnosis, more research, improved treatment options, and eventual progress toward a cure for uterine fibroids.
Overall sentiment around the bill is strongly supportive and noncontroversial based on the text and available context. The resolution presents fibroid awareness as a public health issue affecting many women and emphasizes the value of informing residents and reducing the burden of the condition. No committee debate, recorded votes, or opposition are available in the provided materials.
The main point of emphasis is health awareness rather than policy change. Because the measure is a resolution naming an awareness month, there is little room for substantive contention in the available record. Any potential concerns would likely relate to whether symbolic resolutions should be used for public health messaging, but no such objections appear in the provided context.
This resolution has no direct statutory impact and does not amend Florida law. It simply designates July 2025 as Fibroid Awareness Month, which may be used by state agencies, advocates, and health organizations for outreach and education about uterine fibroids, women’s health, reproductive health, and treatment options.
The available text suggests a positive, supportive sentiment. The resolution is framed as a public health awareness measure, with language emphasizing the prevalence and seriousness of uterine fibroids and the benefits of education, research, and improved treatment. No votes, amendments, or committee objections are provided, so there is no evidence of controversy in the record supplied.
No notable contention is shown in the provided materials. The bill is a ceremonial resolution, so it does not raise fiscal, regulatory, or enforcement disputes. If any disagreement existed, it would most likely concern the use of a formal legislative resolution for awareness messaging rather than substantive health policy, but no such criticism appears in the text or context.